Clinical Trials Directory

Trials / Conditions / Adult Acute Myeloid Leukemia With Maturation

Adult Acute Myeloid Leukemia With Maturation

11 registered clinical trials studyying Adult Acute Myeloid Leukemia With Maturation.

StatusTrialSponsorPhase
CompletedCytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
NCT01870596
National Cancer Institute (NCI)Phase 2
Active Not RecruitingDecitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT01627041
National Cancer Institute (NCI)Phase 2
CompletedTipifarnib in Treating Older Patients With Acute Myeloid Leukemia
NCT01361464
National Cancer Institute (NCI)Phase 2
CompletedCaspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother
NCT01307579
Children's Oncology GroupPhase 3
TerminatedAzacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My
NCT01260714
National Cancer Institute (NCI)Phase 1
CompletedBusulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit
NCT01168219
National Cancer Institute (NCI)Phase 2
Active Not RecruitingAzacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leuke
NCT00658814
National Cancer Institute (NCI)Phase 2
CompletedVeliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu
NCT00588991
National Cancer Institute (NCI)Phase 1
CompletedTipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Ph
NCT00383474
National Cancer Institute (NCI)Phase 1
CompletedSorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast
NCT00217646
National Cancer Institute (NCI)Phase 1
CompletedTipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
NCT00093470
National Cancer Institute (NCI)Phase 3